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A 42-year-old northern Thai man who recently migrated to Australia developed transient sick sinus 
syndrome soon after institution of treatment with Kaletra (liponavir/ritonavir) and Kivexa 
(abacavir/lamivudine) is presented. His most recent CD4 count was 390 cells/l, and he was taking 
no other medications, nor any herbal medicines. He presented with dizziness to the Emergency 
Department after 3 doses of Kaletra (and 2 of Kivexa). There was no history of any cardiac 
conditions and the only other history of note is a positive VDRL test, and Herpes Zoster 6 months 
ago.  
On admission he was bradycardic with pulse rate of 42/minute. His ECG demonstrated sinus arrest 
with junctional escape rhythm which later changed into atrial fibrillation followed by sinus 
bradycardia. Three days after stopping his medications he reverted to normal sinus rhythm. To our 
knowledge only 4 similar cases have been described in the literature, and 3 occurred in Japanese 
individuals. All of these cases were associated with the introduction of lopinavir/ritonavir. In 
contrast to our patient, however, all of the previously described cases were on various other 
medications apart from antiretrovirals, and the mechanism of cardiac conduction defects with these 
agents has not yet been elucidated.  
Our case occurred in a man who is HLAB57-negative, and it is proposed that lopinavir/ritonavir is 
the cause of this mans sinus arrhythmia. 
Even though the numbers of affected individuals are small, 3 out of 4 individuals were of Asian 
origin which raises the question about genetic propensity to this particular manifestation of this 
particular combination of antiretroviral (liponavir/ritonavir).  
 
 
